Shining a Light on UV Disinfection

Ultraviolet, more commonly referred to as simply UV, light is gaining popularity as an additional measure offices and schools can take to effectively control and prevent infection indoors in the era of the novel coronavirus.

Dr. Fiona Collins and Dr. Scott Cohen of the HealthFirst Medical Advisory Board joined the HealthFirst podcast to outline the advantages and downsides of major UV technologies seeing more widespread use in the wake of the COVID-19 pandemic.

While different types of UV disinfection technology can effectively disinfect both air and surfaces, the technology is not without its potential downsides. One key consideration is safety, specifically regarding dosage levels and what amount of exposure is safe for occupants of a space.

While high-intensity UV-C solutions can be used in empty rooms to disinfect them rather thoroughly, another common challenge is shadows.

“Typically, what happens is there are two cycles – one in one direction, one in the other, and, sometimes, even more to make sure those shadows are treated,” Cohen said. “You really can’t be exposed to UV-C in this high-intensity fashion. … You cannot be in the room.”

While low-intensity options could be safer, it’s important to understand your space, the specific device and solution you’re looking into, and how to make a space as safe as possible without putting inhabitants in danger.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Recent Episodes

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…